Sandoz Bolsters US Ophthalmic Portfolio With Aflibercept Approval

Launch Date Of Eylea Biosimilar Uncertain As ‘Complicated’ Court Proceedings Continue

 
• By Dave Wallace

Sandoz has celebrated a US FDA approval for its Enzeevu biosimilar rival to Eylea. However, ongoing court proceedings make launch timing uncertain.

USA flag reflected in eye
Sandoz has received FDA approval for its Enzeevu rival to Eylea • Source: Shutterstock

More from Biosimilars

More from Products